Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Insmed Q3 2026 Results: Net Loss of $100M, Loss Narrows

Insmed reported a significant increase in product revenues to $524.4 million for the third quarter of 2026, compared to $142.3 million in the prior year period. Despite the revenue growth, the company recorded a net loss of $100.3 million for the quarter, though this was a substantial improvement from the $370.0 million net loss in Q3 2025, primarily driven by higher sales and a decrease in the fair value of contingent consideration.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue524.4142.3
Profit before tax-97.7-368.7
Net income-100.3-370.0
EPS (diluted, $ a share)$-0.46$-1.75

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+268.4%
Operating margin-17.0%
Source

10-Q filed with the SEC, NASDAQ: INSM. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Insmed Inc: key numbers

Share price
$121.86Close, Nov 17
Market cap
$26.7B
Shares outstanding
219.38MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Insmed Inc

All →
7:02 AM ET 8-K
Financial Results

Insmed Financial Results

Insmed reported third-quarter 2026 total revenues of $524.4 million, driven by strong commercial momentum for BRINSUPRI and ARIKAYCE. The company raised its full-year 2026 revenue guidance for both products following the successful launch of BRINSUPRI in Japan and continued growth in the U.S. market.

“The third quarter marked another period of meaningful progress, defined by commercial momentum, regulatory achievements, and advancement across our diversified pipeline. BRINSUPRI’s U.S. launch continues to exceed expectations and ARIKAYCE continues to grow while in its ninth year on the market. This performance supports our decision to raise the low end of our full-year 2026 revenue guidance for both products.”

Will Lewis, Chair and Chief Executive Officer of Insmed
7:01 AM ET 8-K
Leadership Change

Insmed Leadership Change

Insmed Incorporated appointed Paul Hudson, former CEO of Sanofi and Novartis, and Utpal Koppikar, CFO of Verily Health, to its Board of Directors effective October 19, 2026. Both directors will receive an annual cash retainer of $65,000 plus committee fees and an initial RSU grant valued at approximately $585,000. The appointments add significant global biopharma leadership and financial expertise to the board as the company advances its rare disease pipeline.

7:01 AM ET 8-K
Leadership Change

Insmed Leadership Change

Sara Bonstein is stepping down as Chief Financial Officer of Insmed, effective October 30, 2026, to pursue a broader leadership role. The company has initiated a search for a successor and reaffirmed its full-year 2026 revenue guidance for BRINSUPRI and ARIKAYCE.

Earnings call
Oct 29, 2026, 8:00 AM ET

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.